$144 Million

Myovant Sciences

Follow-on Offering

Bookrunner, May 2019

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and prostate cancer. The Company’s lead product candidate, relugolix, is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. Relugolix is currently being developed in multiple Phase 3 clinical trials across three distinct indications: heavy menstrual bleeding associated with uterine fibroids, with data expected in Q3 2019; advanced prostate cancer, with data expected in Q4 2019; and pain associated with endometriosis, with data expected in Q1 2020. Myovant was launched in June 2016 by Roivant Sciences Ltd and Takeda Pharmaceutical Company Limited.